SCIENTURE HOLDINGS INC (SCNX) Stock Price & Overview

NASDAQ:SCNX • US80880X1046

Current stock price

0.452 USD
-0.02 (-3.29%)
Last:

The current stock price of SCNX is 0.452 USD. Today SCNX is down by -3.29%. In the past month the price increased by 8.57%. In the past year, price decreased by -68.63%.

SCNX Key Statistics

52-Week Range0.372 - 3.1699
Current SCNX stock price positioned within its 52-week range.
1-Month Range0.372 - 0.6443
Current SCNX stock price positioned within its 1-month range.
Market Cap
18.365M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.72
Dividend Yield
N/A

SCNX Stock Performance

Today
-3.29%
1 Week
+17.97%
1 Month
+8.57%
3 Months
-22.79%
Longer-term
6 Months -50.46%
1 Year -68.63%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

SCNX Stock Chart

SCIENTURE HOLDINGS INC / SCNX Daily stock chart

SCNX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SCNX. When comparing the yearly performance of all stocks, SCNX is a bad performer in the overall market: 93.39% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SCNX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to SCNX. SCNX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SCNX Earnings

Next Earnings DateMar 24, 2026
Last Earnings DateNov 12, 2025
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

SCNX Forecast & Estimates

For the next year, analysts expect an EPS growth of -171.11% and a revenue growth -93.55% for SCNX


Analysts
Analysts82.86
Price TargetN/A
EPS Next Y-171.11%
Revenue Next Year-93.55%

SCNX Groups

Sector & Classification

Index Membership

SCNX Financial Highlights

Over the last trailing twelve months SCNX reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by -283.71% compared to the year before.


Income Statements
Revenue(TTM)653.50K
Net Income(TTM)-20.55M
Industry RankSector Rank
PM (TTM) N/A
ROA -19.61%
ROE -24.86%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%85.81%
Sales Q2Q%809.24%
EPS 1Y (TTM)-283.71%
Revenue 1Y (TTM)-73.17%

SCNX Ownership

Ownership
Inst Owners3.72%
Shares40.63M
Float33.79M
Ins Owners10.81%
Short Float %4.12%
Short Ratio0.36

SCNX Competitors/Peers

The largest stocks on the US markets in the "Health Care Technology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
VEEV VEEVA SYSTEMS INC-CLASS A21.2429.404B
WAY WAYSTAR HOLDING CORP14.924.631B
DOCS DOXIMITY INC-CLASS A14.884.501B
HTFL HEARTFLOW INC N/A1.745B
LFMDP LIFEMD INC - LFMD 8 7/8 PERP N/A1.097B
CCLDO CARECLOUD INC - CCLD 8 3/4 PERP230.291.082B
CERT CERTARA INC12.991.058B
TDOC TELADOC HEALTH INC N/A958.008M
SDGR SCHRODINGER INC N/A923.613M
GDRX GOODRX HOLDINGS INC-CLASS A6.1767.357M
PHR PHREESIA INC16.99661.381M
HSTM HEALTHSTREAM INC27.92596.008M
EVH EVOLENT HEALTH INC - A11.28333.804M

About SCNX

Company Profile

SCNX logo image Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Company Info

IPO: 2020-02-18

SCIENTURE HOLDINGS INC

20 Austin Blvd.

Commack NEW YORK US

Employees: 14

SCNX Company Website

SCNX Investor Relations

Phone: 18002610281

SCIENTURE HOLDINGS INC / SCNX FAQ

What does SCIENTURE HOLDINGS INC do?

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.


What is the current price of SCNX stock?

The current stock price of SCNX is 0.452 USD. The price decreased by -3.29% in the last trading session.


Does SCIENTURE HOLDINGS INC pay dividends?

SCNX does not pay a dividend.


What is the ChartMill rating of SCIENTURE HOLDINGS INC stock?

SCNX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Should I buy SCNX stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCNX.


Can you provide the market cap for SCIENTURE HOLDINGS INC?

SCIENTURE HOLDINGS INC (SCNX) has a market capitalization of 18.36M USD. This makes SCNX a Nano Cap stock.


What is the next earnings date for SCNX stock?

SCIENTURE HOLDINGS INC (SCNX) will report earnings on 2026-03-24.